JAZZ (Jazz Pharmaceuticals) Cyclically Adjusted PS Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JAZZ Jazz Pharmaceuticals PLC JAZZ
73 GF Score
Price $261.62
GF Value $150.30
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Jazz Pharmaceuticals  (NAS:JAZZ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Jazz Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Jazz Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.40 4.41 2.97 2.67 3.28

Jazz Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.17 2.63 3.28 3.53 0.00

JAZZ vs BBIO, ASND, EXEL: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


JAZZ
73GF Score
Jazz Pharmaceuticals PLC JAZZ
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Jazz Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Jazz Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=17.411/128.6700*128.6700
=17.411

Current CPI (Jun. 2026) = 128.6700.

Jazz Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 6.055 100.274 7.770
201612 6.499 99.676 8.389
201703 6.147 100.374 7.880
201706 6.417 100.673 8.202
201709 6.704 100.474 8.585
201712 7.132 100.075 9.170
201803 7.268 100.573 9.298
201806 8.146 101.072 10.370
201809 7.588 101.371 9.631
201812 7.888 100.773 10.072
201903 8.750 101.670 11.074
201906 9.301 102.168 11.714
201909 9.361 102.268 11.778
201912 10.160 102.068 12.808
202003 9.556 102.367 12.011
202006 10.068 101.769 12.729
202009 10.685 101.072 13.603
202012 11.640 101.072 14.818
202103 10.405 102.367 13.079
202106 12.647 103.364 15.743
202109 13.676 104.859 16.781
202112 14.575 106.653 17.584
202203 12.935 109.245 15.235
202206 14.707 112.779 16.779
202209 14.982 113.504 16.984
202212 15.416 115.436 17.183
202303 12.102 117.609 13.240
202306 13.018 119.662 13.998
202309 13.636 120.749 14.531
202312 14.526 120.749 15.479
202403 14.423 120.990 15.339
202406 14.705 122.318 15.469
202409 16.699 121.594 17.671
202412 17.695 122.439 18.595
202503 14.718 123.405 15.346
202506 17.087 124.492 17.660
202509 18.279 124.810 18.844
202512 19.619 125.770 20.071
202603 16.171 127.830 16.277
202606 17.411 128.670 17.411

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of $261.62 is trading 74.1% above its estimated GF Value™ of $150.30. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for JAZZ:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $150.30 vs. price of $261.62 (74.1% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for JAZZ

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$261.62
Price
$150.30
GF Value